This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Scholar Rock’s 8K filing here.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Featured Stories
- Five stocks we like better than Scholar Rock
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- Options Trading – Understanding Strike Price
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- How Investors Can Find the Best Cheap Dividend Stocks
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
